Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer Pharmaceutical Business ReviewThis combo is approved for adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer.OncologyRead full story pharminent September 7, 2026 (Last updated: September 9, 2026) Pharmaceutical Business Review This combo is approved for adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer. Oncology Read full story Post navigation Previous: Major trial of Roche Alzheimer’s drug kicks off in EuropeNext: Novartis hit as Lp(a) drug fails cardio outcomes trial Related Stories Regulatory Ionis nets Zanvastro US approval in first for Alexander disease pharminent September 4, 2026 Regulatory FDA OKs Takeda, Protagonist drug for rare blood cancer pharminent August 31, 2026 Regulatory FDA clears Takeda, Protagonist’s first-in-class PV drug pharminent August 31, 2026